Todays Report: Today, Strs Ohio sells partial stakes of Illumina Inc. (ILMN)

Today, Strs Ohio sells partial stakes of Illumina Inc. (ILMN)

Strs Ohio decreased its stake in Illumina Inc. (NASDAQ:ILMN) by 38.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,105 shares of the life sciences company’s stock after selling 1,337 shares during the period. Strs Ohio’s holdings in Illumina were worth $382,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Checchi Capital Advisers LLC increased its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in Illumina by 1.1% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,698 shares of the life sciences company’s stock valued at $467,000 after buying an additional 39 shares in the last quarter. Nippon Life Insurance Co. increased its stake in Illumina by 0.5% in the second quarter. Nippon Life Insurance Co. now owns 7,877 shares of the life sciences company’s stock valued at $1,106,000 after buying an additional 40 shares in the last quarter. Regent Investment Management LLC increased its stake in Illumina by 1.8% in the second quarter. Regent Investment Management LLC now owns 4,250 shares of the life sciences company’s stock valued at $597,000 after buying an additional 75 shares in the last quarter. Finally, Cullen Frost Bankers Inc. increased its stake in Illumina by 1.1% in the second quarter. Cullen Frost Bankers Inc. now owns 6,770 shares of the life sciences company’s stock valued at $951,000 after buying an additional 75 shares in the last quarter. Institutional investors own 93.52% of the company’s stock.

Illumina Inc. (NASDAQ:ILMN) traded up 0.57% during trading on Friday, hitting $135.19. 342,958 shares of the stock traded hands. Illumina Inc. has a one year low of $127.10 and a one year high of $196.47. The company has a 50-day moving average price of $140.46 and a 200 day moving average price of $152.80. The stock has a market cap of $19.86 billion, a PE ratio of 45.37 and a beta of 1.24.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.10. The business had revenue of $607 million for the quarter, compared to the consensus estimate of $628.06 million. Illumina had a net margin of 18.72% and a return on equity of 23.76%. Illumina’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $0.80 earnings per share. Analysts expect that Illumina Inc. will post $3.32 earnings per share for the current year.

Several equities research analysts have issued reports on the stock. Argus boosted their price objective on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, August 8th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Barclays PLC set a $142.00 target price on shares of Illumina and gave the stock an “equal weight” rating in a research report on Tuesday, October 11th. Cantor Fitzgerald reissued a “hold” rating and set a $155.00 target price on shares of Illumina in a research report on Thursday, November 3rd. Finally, BTIG Research reissued a “hold” rating on shares of Illumina in a research report on Thursday, November 3rd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. Illumina presently has an average rating of “Hold” and an average price target of $152.88.

In other news, Director Robert S. Epstein sold 300 shares of the firm’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total value of $52,287.00. Following the sale, the director now owns 6,924 shares in the company, valued at $1,206,783.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $171.25, for a total transaction of $102,750.00. Following the completion of the sale, the director now owns 17,065 shares in the company, valued at approximately $2,922,381.25. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Related posts

Leave a Comment